Sean Wharton

ORCID

Publication Activity (10 Years)

Years Active: 2020-2024
Publications (10 Years): 21

Top Venues

Diabetes, obesity & metabolism

Obesity (Silver Spring, Md.)

Postgraduate medicine

International journal of obesity (2005)

Wharton Medical Clinic

University of Toronto (PHD)

This page only lists publications with an associated author ORCID identifier.

Affiliation History

Wharton Medical Clinic

Canada

Clinical trials - Primary Investigator

The Wharton Medical Clinic Diabetes and Weight Managment Centre

Canada

Medical Director

Michael Garon Hospital

Canada

Internal Medicine :: Medicine

Education History

University of Toronto

Canada

PHD :: Medicine

University of Toronto

Canada

PHD :: Faculty of Pharmacy

Publications

Domenica M Rubino, Jakob Bue Bjorner, Naveen Rathor, Arya M Sharma, Lisa von Huth Smith, Sean Wharton, Thomas A Wadden, Niels Zeuthen, Ronette L Kolotkin
Effect of semaglutide 2.4 mg on physical functioning and weight- and health-related quality of life in adults with overweight or obesity: Patient-reported outcomes from the STEP 1-4 trials. Diabetes, obesity & metabolism 26 (7) (2024)
Domenica M Rubino, Jakob Bue Bjorner, Naveen Rathor, Arya M Sharma, Lisa von Huth Smith, Sean Wharton, Thomas A Wadden, Niels Zeuthen, Ronette L Kolotkin
Effect of semaglutide 2.4 mg on physical functioning and weight- and health-related quality of life in adults with overweight or obesity: Patient-reported outcomes from the STEP 1-4 trials. Diabetes, obesity & metabolism (2024)
Domenica M Rubino, Jakob Bue Bjorner, Naveen Rathor, Arya M Sharma, Lisa von Huth Smith, Sean Wharton, Thomas A Wadden, Niels Zeuthen, Ronette L Kolotkin
Effect of semaglutide 2.4 mg on physical functioning and weight- and health-related quality of life in adults with overweight or obesity: Patient-reported outcomes from the STEP 1-4 trials. Diabetes, obesity & metabolism 26 (7) (2024)
Sean Wharton, Rachel L Batterham, Meena Bhatta, Silvio Buscemi, Louise N Christensen, Juan P Frias, Esteban Jódar, Kristian Kandler, Georgia Rigas, Thomas A Wadden, W Timothy Garvey
Two-year effect of semaglutide 2.4 mg on control of eating in adults with overweight/obesity: STEP 5. Obesity (Silver Spring, Md.) 31 (3) (2023)
Anders Strathe, Deborah Bade Horn, Malte Selch Larsen, Domenica M Rubino, Rasmus Sørrig, Marie Thi Dao Tran, Sean Wharton, Rune Viig Overgaard
A model-based approach to predict individual weight loss with semaglutide in people with overweight or obesity. Diabetes, obesity & metabolism (2023)
Sean Wharton, Rachel L Batterham, Meena Bhatta, Silvio Buscemi, Louise N Christensen, Juan P Frias, Esteban Jódar, Kristian Kandler, Georgia Rigas, Thomas A Wadden, W Timothy Garvey
Two-year effect of semaglutide 2.4 mg on control of eating in adults with overweight/obesity: STEP 5. Obesity (Silver Spring, Md.) 31 (3) (2023)
Anastassia Amaro, Danny H Sugimoto, Sean Wharton
Efficacy and safety of semaglutide for weight management: evidence from the STEP program. Postgraduate medicine 134 (sup1) (2023)
Sean Wharton, Rachel L Batterham, Meena Bhatta, Silvio Buscemi, Louise N Christensen, Juan P Frias, Esteban Jódar, Kristian Kandler, Georgia Rigas, Thomas A Wadden, W Timothy Garvey
Two-year effect of semaglutide 2.4 mg on control of eating in adults with overweight/obesity: STEP 5. Obesity (Silver Spring, Md.) (2023)
Sean Wharton, Rachel L Batterham, Meena Bhatta, Silvio Buscemi, Louise N Christensen, Juan P Frias, Esteban Jódar, Kristian Kandler, Georgia Rigas, Thomas A Wadden, W Timothy Garvey
Two-year effect of semaglutide 2.4 mg on control of eating in adults with overweight/obesity: STEP 5. Obesity (Silver Spring, Md.) 31 (3) (2023)
Carel W le Roux, Emily R Hankosky, Duzhe Wang, Raleigh E Malik, Maria Yu, Ana Hickey, Hong Kan, Mathijs C Bunck, Adam Stefanski, Luis-Emilio Garcia-Perez, Sean Wharton
Tirzepatide 10 and 15 mg compared with semaglutide 2.4 mg for the treatment of obesity: An indirect treatment comparison. Diabetes, obesity & metabolism (2023)
Janine V Kyrillos, Patrick M O'Neil, Sean Wharton
Introducing an important therapy for obesity to primary care: once-weekly subcutaneous semaglutide 2.4 mg. Postgraduate medicine 134 (sup1) (2023)
John P H Wilding, Rachel L Batterham, Melanie Jane Davies, Luc F Van Gaal, Kristian Kandler, Katerina Konakli, Ildiko Lingvay, Barbara M McGowan, Tugce Kalayci Oral, Julio Rosenstock, Thomas A Wadden, Sean Wharton, Koutaro Yokote, Robert F Kushner, null null
Weight regain and cardiometabolic effects after withdrawal of semaglutide: The STEP 1 trial extension. Diabetes, obesity & metabolism 24 (8) (2022)
Jennifer L Kuk, Elham Kamran, Sean Wharton
Association between weight-loss history and weight loss achieved in clinical obesity management: Retrospective chart review. Obesity (Silver Spring, Md.) 30 (10) (2022)
Jennifer L Kuk, Rebecca A G Christensen, Elham Kamran Samani, Sean Wharton
Predictors of Weight Loss and Weight Gain in Weight Management Patients during the COVID-19 Pandemic. Journal of obesity 2021 (2021)
Sean Wharton, Melanie Jane Davies, Dror Dicker, Ildiko Lingvay, Lawrence A Leiter, Domenica M Rubino, Sue D Pedersen
Managing the gastrointestinal side effects of GLP-1 receptor agonists in obesity: recommendations for clinical practice. Postgraduate medicine (2021)
Sean Wharton, Salvatore Calanna, Melanie Jane Davies, Dror Dicker, Bryan Goldman, Ildiko Lingvay, Lawrence A Leiter, Domenica M Rubino, Mette Thomsen, Thomas A Wadden, Sue D Pedersen
Gastrointestinal tolerability of once-weekly semaglutide 2.4 mg in adults with overweight or obesity, and the relationship between gastrointestinal adverse events and weight loss. Diabetes, obesity & metabolism 24 (1) (2021)
Sean Wharton, Peter Yin, Melonie Burrows, Errol Gould, Jessica Blavignac, Rebecca A G Christensen, Elham Kamran, Fernando Camacho, Maxime Barakat
Extended-release naltrexone/bupropion is safe and effective among subjects with type 2 diabetes already taking incretin agents: a post-hoc analysis of the LIGHT trial. International journal of obesity (2005) 45 (8) (2021)
Sean Wharton, Arnie Astrup, Lars Endahl, Michael Ernest John Lean, Altynai Satylganova, Dorthe Skovgaard, Thomas A Wadden, John P H Wilding
Estimating and reporting treatment effects in clinical trials for weight management: using estimands to interpret effects of intercurrent events and missing data. International journal of obesity (2005) 45 (5) (2021)
Robert F Kushner, Salvatore Calanna, Melanie Davies, Dror Dicker, W Timothy Garvey, Bryan Goldman, Ildiko Lingvay, Mette Thomsen, Thomas A Wadden, Sean Wharton, John P H Wilding, Domenica Rubino
Semaglutide 2.4 mg for the Treatment of Obesity: Key Elements of the STEP Trials 1 to 5. Obesity (Silver Spring, Md.) 28 (6) (2020)
Sean Wharton, Christiane L Haase, Elham Kamran, Aiden Liu, Johanna Mancini, Drew Neish, Arash Pakseresht, G Sarah Power, Rebecca A G Christensen
Real-world persistence with liraglutide 3.0 mg for weight management and the SaxendaCare® patient support program. Obesity science & practice 6 (4) (2020)
Sean Wharton, Christiane L Haase, Elham Kamran, Aiden Liu, Johanna Mancini, Drew Neish, Arash Pakseresht, G Sarah Power, Rebecca A G Christensen
Weight loss and persistence with liraglutide 3.0 mg by obesity class in the real-world effectiveness study in Canada. Obesity science & practice 6 (4) (2020)

Sean Wharton.css-eqlu8i{font-size:small;padding-left:4px;}

Publication Activity (10 Years)

Top Topics

Top Venues

Sean Wharton